New Products
Control Genomic DNAs
(Jan. 2009)
BioChain's
Control Genomic DNAs are isolated from human and different
animal species, genomic DNAs from male and female of each
species are available.
DNA Methylation Detection Kit
(Nov. 2008)
BioChain's
DNA methylation detection kit offers a fast, efficient and
convenient alternative to traditional bisulfite conversions. Our
kit provides users with a true endogenous human positive control
which eliminates any ambiguity in validating results. The
positive control has been tested in over 15 different human
tissues. We have optimized our protocol to minimize DNA
degradation, reagent preparation, and conversion time. Our
protocol guarantees > 99 % conversion of cytosine to uracil and
> 99 % CpG protection, as calculated by sequencing, and is
sensitive over a range of 2 µg - 500
pg of DNA. In less than 3 hours, users can obtain high quality
bisulfite modified DNA ready for analysis by PCR, sequencing, or
microarrays.
FFPE Tissue DNA Extraction Kit
(Nov. 2008)
BioChain's
FFPE Tissue DNA Extraction Kit allows for facile and efficient
deoxyribonucleic acid extraction from FFPE tissues. All
necessary reagents for DNA extractions in FFPE tissue specimens
are provided, including FFPE tissue lysis buffer, proteinase K,
and an actin control primer for control qPCR reactions. The kit
contains sufficient reagents for 100 FFPE tissue DNA extraction
reactions.
FFPE
Tissue RNA Extraction Kit
(Nov. 2008)
BioChain's
FFPE Tissue RNA Extraction Kit allows for facile and efficient
ribonucleic acid extraction from FFPE tissues. All necessary
reagents for RNA extractions in FFPE tissue specimens are
provided, including FFPE tissue lysis buffer, proteinase K, and
an actin control primer for control RT-qPCR reactions. The kit
contains sufficient reagents for 100 FFPE tissue RNA extraction
reactions.
Blood DNA Isolation Kit
(Nov. 2008)
BioChain's
Blood DNA Isolation Kit offers a fast, efficient, and convenient
alternative to traditional phenol or protease treatment. Our
protocol guarantees isolate DNA from 50 µl to 200 µl whole blood
sample. In less than 15 minutes, users can obtain pure DNA
(>20kb) ready for analysis by PCR, sequencing, or microarrays.
Serum DNA Isolation Kit
(Nov. 2008)
BioChain's
Serum DNA Isolation kit offers a fast, efficient, and convenient
alternative to traditional phenol or protease treatment. Our
protocol guarantees isolate DNA from 200 µl serum or plasma
samples. In less than 15 minutes, users can obtain pure DNA
ready for analysis by PCR, sequencing, or microarrays.
Calcium Channel Cell Lines (Oct. 2008)
Voltage-gated calcium channels control both
electrical signal transduction and intracellular calcium level.
They can be generally classified into three families, designated
as CaV1~3 families. T-type Ca2+ channels, or
low-voltage-activated calcium channels, belong to the CaV3
family ion channels. They are activated upon minute voltage
changes near the resting membrane potential. Their activation
has been shown to mediate cardiac action potential, neuronal
rebound burst firing and synchronization of thalamic activity;
their dysfunction has been associated with various neurological
and cardiovascular disorders. Their interaction with potential
antagonists and inhibitors has been associated with
pharmacological treatments for pain and epilepsy.
Rodent Custom Services (Oct. 2008)
BioChain has completed the establishment of a
rodent facility in the San Francisco Bay area. Our facility is
currently hosting major strains of inbred and outbred mice,
rats, and hamsters. Our facility is fully AAALAC accredited.
With our state-of-the-art facility and experienced scientists
and technicians, we are well-positioned as a premium service
provider in contract animal research. BioChain Institute is
dedicated to providing our clients a wide range of preclinical
contract animal research services designed to support various
biological and pharmaceutical studies. These services range from
pharmacokinetics, toxicology studies to the complete outsourcing
of entire animal studies.
Mouse Feeder Cells (Sep. 2008)
Biochain provides mouse
embryonic fibroblast (MEF) cells as feeder layers for stem cell
culture to the research community. We have a wide range of
selection of MEF cells including neomycin resistant, DR4
(resistant to neomycin, hygromycin, puromycin and 6-thioguanine)
and CF-1 MEF cells. We have both untreated or gamma irradiated
MEF cells. Every single batch of MEF cells is tested for its
ability to support undifferentiated mESC growth and is
mycoplasma negative. Early passages (P2) are provided for
further expansion if more cells are needed.
Xenograft Service (Sep. 2008)
Living
Tumor xenograft models are developed using human tumor tissues
grafted in subrenal capsules of SCID mice. The human tumor
tissues are developed into transplantable tumor tissue lines.
These tumor tissue lines offer a sustainable tumor source for
xenograft models. The model is in many aspects superior to
conventional tumor model systems which are based on cultured
cancer cell lines. There are over 100 established tumor lines
available from Biochain.
Primate Animal Model Services (Sep. 2008)
According
to FDA regulations, all drug candidates for Neurological
diseases, such as Alzheimer's disease and Parkinson's disease,
must pass nonhuman primate animal tests before processing into
clinical trials. In addition, all cell-based therapies and
gene-therapies are also required to go through nonhuman primate
animal tests before advancing to a phase I clinical trial.
Nonhuman primate animal models need to be established for the
research of the following important human diseases, such as
AIDS, SARS, autoimmune system diseases, old age diseases, and
other gene defective diseases. Biochain has teamed up with
contract research organizations (CROs), which are fully
accredited by AAALAC international, and exclusively focus on
primate resources. We have a very strong team
of scientists, researchers, veterinarians, and technicians, who
are actively engaged in developing nonhuman primate models for
studies of drug safety, drug pharmacokinetics, drug efficacy,
and cell and gene therapies, particularly for neurological
disorders and aging-related diseases.